Anti-CD3/EpCAM antibody-GLP-1 fusion protein(Nanjing University)

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug NameAnti-CD3/EpCAM antibody-GLP-1 fusion protein(Nanjing University)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-EpCAMAnti-CD3Glucagon-like peptide 1 receptor agonists

TargetsEpithelial cell adhesion moleculeT cell surface glycoprotein CD3Glucagon-like peptide 1 receptor

Therapy Area/IndicationsPrimary MyelofibrosisKidney NeoplasmsPancreatic Neoplasms +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaPreclinical

Originator CompaniesNanjing University

China Registration ClassN/A

Develop Information

Active CompaniesNanjing University

Inactive CompaniesN/A

Active IndicationsPrimary MyelofibrosisKidney NeoplasmsPancreatic Neoplasms +[6]

Inactive IndicationsN/A

Other Information

ATC CodeN/A